Loco-Regional Irradiation for Patients With Biopsy-Proven Axillary Node Involvement Who Become Node-Negative After Neoadjuvant Chemotherapy
Eleftherios Mamounas, MD, Orlando Health Cancer Institute, Florida, discussed primary results from the NRG Oncology/NSABP B-51/RTOG 1304 study. Results indicated that adjuvant regional nodal irradiation including the chest wall after mastectomy and with whole breast irradiation after breast conserving surgery did not improve survival outcomes among patients with biopsy-proven axillary node involvement that convert to node-negative after neoadjuvant chemotherapy.
These results were first presented at the 2023 San Antonio Breast Cancer Symposium.
Source:
Mamounas E, Bandos H, White J, et al. Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304. Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9; San Antonio, Texas. Abstract GS02-07